SCHEMBL6565677

SCHEMBL6565677

CCOC(=O)CSc1nc(Cl)cc(N(C)Cc2ccc(Cl)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
CYP3A4 P08684 1/20 0.45
PTGS2 P35354 1/20 0.45
MAPT P10636 1/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44
KDM4E B2RXH2 5/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
HSD17B10 Q99714 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
MITF O75030 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6565640 0.85 CYP1A2 (0.49) ALOX5CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL6827151 0.79 KDM4E (0.58) ALOX5MAPTKDM4ELMNAGAA
SCHEMBL6565474 0.76 ALOX5 (0.53) ALOX5CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL6561975 0.75 ALOX5 (0.70) ALOX5CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL6562061 0.73 L3MBTL1 (0.61) ALOX5MAPTKDM4ELMNAGAA
SCHEMBL6563880 0.72 USP2 (0.51) ALOX5CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL6563445 0.71 ALOX5 (0.52) ALOX5CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL6563451 0.71 ALOX5 (0.52) ALOX5CYP1A2CYP2C9CYP2C19CYP3A4
SCHEMBL6565776 0.71 L3MBTL1 (0.70) ALOX5CYP1A2CYP2C9CYP2C19PTGS2
SCHEMBL11871997 0.70 KDM4E (0.53) CYP1A2CYP2C9CYP2C19CYP3A4PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399426-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION Active Pass Pharmaceuticals, Inc. (CA) 2004-03-24 EP disclosed
US-20030191144-A1 Compounds, compositions and methods for modulating beta-amyloid production ACTIVE PASS PHARMACEUTICALS, INC. (CA) 2003-10-09 US disclosed
US-20030125338-A1 Compounds, compositions and methods for modulating beta-amyloid production ACTIVE PASS PHARMACEUTICALS, INC. (CA) 2003-07-03 US disclosed
WO-2002100836-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING BETA-AMYLOID PRODUCTION ACTIVE PASS PHARMACEUTICALS, INC. (CA) 2002-12-19 WO disclosed
US-3940394-A ANTILIPEMIC SANTILLI ARTHUR A 1976-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125338-A1 Compounds, compositions and methods for modulating beta-amyloid production APP, PPARA, PPARG ALOX5 197/4885CYP1A2 2179/4885CYP2C9 3692/4885
US-20030191144-A1 Compounds, compositions and methods for modulating beta-amyloid production APP, PPARA, PPARG ALOX5 197/4885CYP1A2 2179/4885CYP2C9 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.